Global Digital pathology market was valued at $1,442.0 million in 2025 and is projected to reach $10,193.4 million by 2035, growing at a CAGR of 21.7% during the forecast period (2026-2035). Artificial Intelligence (AI) and Machine Learning (ML) are increasingly integrated into digital pathology workflows, representing a key trend in the global market. These technologies are being embedded within pathology software to automate image analysis, detect anomalies, and classify tissue samples with greater precision. AI/ML tools also support the quantification of biomarkers and tumor characteristics, enabling more accurate and reproducible assessments. By reducing inter-observer variability, these systems contribute to faster and more consistent diagnostic outcomes.

European meal replacement products market was valued at $5.2 billion in 2024 and is projected to reach $11.4 billion by 2035, growing at a CAGR of 7.4% during the forecast period (2025-2035). The European meal replacement products market is supported by strong consumer emphasis on nutritional quality, product safety, and sustainability. Consumers across the region increasingly favor clean-label, organic, plant-based, and nutritionally balanced meal replacements that align with weight management, active lifestyles, and preventive healthcare goals. A well-defined regulatory framework under the European Food Safety Authority (EFSA) ensures strict compliance with ingredient safety, labeling, and nutritional standards, encouraging manufacturers to maintain high transparency and formulation integrity. Additionally, rising adoption of vegan and allergen-free diets, coupled with growing digital retail penetration, is accelerating demand across Western, Central, and Eastern Europe.

Latin America e-commerce logistics market was valued at $34.7 billion in 2025 and is projected to reach $91.9 billion by 2035, growing at a CAGR of 10.3% during the forecast period (2026–2035). Brazil’s fast-expanding e-commerce ecosystem remains a central demand driver for the Latin America e-commerce logistics market, directly influencing parcel volumes, delivery frequency, and service complexity. According to the Brazil Country Commercial Guide prepared by US government agencies, the country’s e-commerce revenue is projected to reach $36.3 billion in 2025, with nearly 94 million Brazilians expected to make online purchases, up by three million year over year. This sustained increase in active online buyers fuels higher demand for forward logistics, urban warehousing, and time-definite transportation services, particularly across domestic operations where same-day and next-day delivery expectations are rising.

Asia-Pacific air ambulance services market was valued at approximately $1.68 billion in 2025 and is projected to reach $4.45 billion by 2035, growing at a CAGR of 10.2% during the forecast period (2026-2035). Strengthening of road safety governance and emergency response frameworks is emerging as an important driver for the Asia Pacific air ambulance services market, particularly in India. The notification of the National Road Safety Board Rules, 2025, by the Ministry of Road Transport and Highways reflects a structured government effort to reduce road accident fatalities and improve post-crash response mechanisms. The Rules mandate coordinated action between the Central and State Governments, focus on safer road infrastructure, and promote the development of a road safety information system. 

US asset performance management market was valued at $610 million in 2025 and is expected to grow to $1,720 million by 2035, registering a CAGR of 10.9% over the 2026–2035 period. The US asset performance management market is increasingly shaped by the rapid integration of cloud computing and artificial intelligence technologies across enterprise operations. These technologies provide the foundational infrastructure and advanced analytics that help organisations monitor asset health, predict failures, optimise maintenance strategies, and improve operational reliability. Cloud platforms deliver scalable storage and compute resources needed for real?time data processing, while AI enhances predictive capabilities that reduce unplanned downtime and extend asset life cycles. Across deployment models and end?users such as government, energy & utilities, healthcare, BFSI, and IT & telecom, this digital shift is strengthening demand for both cloud?based and on?premises APM solutions. 

The North America asset performance management market stood at $760 million in 2025 and is forecast to expand to $2,110 million by 2035, registering a CAGR of 10.8% over the 2026–2035 period. The North America APM market is gaining traction as enterprises expand digital capabilities and integrate advanced technologies that enable predictive and performance?driven asset management. Cloud computing and artificial intelligence (AI) adoption are central to this shift, providing scalable infrastructure and analytics that help organisations monitor asset health, predict failures, and optimise maintenance workflows. 

Global non-small cell lung cancer market was valued at $18.4 billion in 2024 and is growing at a CAGR of 6.4% during the forecast period (2026-2035). Accelerated regulatory approvals for targeted therapies are significantly changing the NSCLC treatment landscape, offering quicker access to new oral treatments for patients with specific genetic mutations who have progressed after prior systemic therapies. This expedited access broadens treatment options in advanced disease stages and stimulates market growth; this regulatory momentum is increasingly reflected in recent approval decisions. For instance, in August 2025, the US FDA granted accelerated approval to Boehringer's HERNEXEOS (zongertinib tablets), the first orally administered targeted therapy for adults with HER2-mutant advanced non-small cell lung cancer (NSCLC) who have previously undergone systemic therapy. 

Europe generic drugs market was valued at $123.4 billion in 2024 and is projected to reach $201.9 billion by 2035, growing at a CAGR of 4.7% during the forecast period (2025-2035). The European generic drug market is increasingly shaped by stringent regulatory frameworks, high consumer expectations for safety and efficacy, and growing demand for cost-effective therapeutic solutions. Oversight by the European Medicines Agency (EMA) and compliance with Good Manufacturing Practices (GMP) ensure high-quality formulations and bioequivalence, fostering trust among patients and healthcare providers. Companies are focusing on innovation in complex generics, specialty dosage forms, and injectable formulations to meet evolving treatment needs, while promoting accessibility and affordability across diverse Western, Central, and Eastern European markets. Rising awareness of sustainable practices and environmentally responsible manufacturing further supports adoption and brand credibility.

Global HFO refrigerant market was valued at $6,267 million in 2025 and is growing at a CAGR of 18.2% during the forecast period (2026-2035). The HVACR industry is undergoing a structural transition toward low-global warming potential (GWP) refrigerants, driven by the need to reduce environmental impact while maintaining system performance across comfort cooling, commercial refrigeration, and transport refrigeration applications. This shift has accelerated the adoption of hydrofluoroolefin (HFO)-based refrigerants, which offer a balance of lower emissions, energy efficiency, and compatibility with existing equipment.

Global fetal bovine serum market was valued at $2.1 billion in 2025 and is growing at a CAGR of 13.3% during the forecast period (2026-2035). Fetal Bovine Serum (FBS) is a common supplement in cell culture, providing essential nutrients, growth factors, and hormones that support cell proliferation and viability. In the context of IVF and fertility treatments, FBS can be used in laboratory processes such as embryo culture and sperm preservation, helping maintain cell health and promoting successful fertilization in vitro. While effective, its use raises ethical concerns and variability issues, leading some laboratories to explore serum-free or humanized alternatives.